RecruitingPhase 1Phase 2NCT05692024

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER


Sponsor

Massachusetts General Hospital

Enrollment

80 participants

Start Date

Mar 21, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (COMMENCE) investigates whether drinking coffee and its metabolites changes the gut bacteria in colorectal cancer survivors — and whether those changes might reduce the risk of cancer coming back. **You may be eligible if...** - You are 18 or older - You have been diagnosed with stage I, II, or III colon or rectal cancer confirmed by biopsy - You have completed your standard cancer treatment (surgery, chemotherapy, and/or radiation) at least 2 months ago - You are willing to follow study procedures and agree to use contraception if applicable **You may NOT be eligible if...** - You are currently receiving any other cancer treatment or enrolled in another interventional study - You are pregnant or trying to become pregnant - You have conditions that would make it unsafe to consume coffee in the amounts required by the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.

Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.

DRUGPlacebo

Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.


Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05692024


Related Trials